Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.
Immunotherapy has reshaped the oncology landscape by enabling the immune system to recognize and eliminate malignant cells. Although immune checkpoint inhibitors (ICIs) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death‐1 (PD‐1), and programmed death‐ligand 1 (PD‐L1) have achieved durable responses in several cancers, their therapeutic benefit remains limited to a subset of patients, largely due to immune evasion, tumor heterogeneity, and immunosuppressive feat...